Rifamycin derivatives effective against drug-resistant microbes
US7247634B2 · kind B2 · utility
2Cited by
5References
53Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 12, 2005 |
| Grant date | Jul 24, 2007 |
| Priority date | — |
| Expiry date | Aug 28, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.